CAR T-Cell Therapy for Multiple Myeloma Market to Witness Upsurge in Growth by 2034 Owing to the Launch of Emerging Therapies | DelveInsight [Yahoo! Finance]
Arcellx, Inc. (ACLX)
Company Research
Source: Yahoo! Finance
The dynamics of the CAR-T cell therapy market for multiple myeloma are anticipated to change due to extensive R&D activities, increased investment in research and development of new CAR-T cell therapies such as anito-cel (Arcellx and Kite), Zevor-cel (CARsgen Therapeutics), arlocabtagene autoleucel (Juno Therapeutics), P-BCMA-ALLO1 (Poseida Therapeutics/Roche), GC012F (Gracell Biopharmaceuticals), and others, and the high effectiveness of CAR-T cell therapies over other conventional drugs. New York, USA, Oct. 08, 2025 (GLOBE NEWSWIRE) -- CAR T-Cell Therapy for Multiple Myeloma Market to Witness Upsurge in Growth by 2034 Owing to the Launch of Emerging Therapies | DelveInsight The dynamics of the CAR-T cell therapy market for multiple myeloma are anticipated to change due to extensive R&D activities, increased investment in research and development of new CAR-T cell therapies such as anito-cel (Arcellx and Kite), Zevor-cel (CARsgen Therapeutics), arlocabtagene autoleucel (Juno The
Show less
Read more
Impact Snapshot
Event Time:
ACLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACLX alerts
High impacting Arcellx, Inc. news events
Weekly update
A roundup of the hottest topics
ACLX
News
- CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting [Yahoo! Finance]Yahoo! Finance
- Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition [Yahoo! Finance]Yahoo! Finance
- Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and ExpositionBusiness Wire
ACLX
Earnings
- 11/5/25 - Miss
ACLX
Sec Filings
- 11/17/25 - Form 4
- 11/5/25 - Form 10-Q
- 11/5/25 - Form 8-K
- ACLX's page on the SEC website